Prof. Höglinger

Prof. Dr. Günter Höglinger

My Research Interest in RESIST

We are generally interested in infections of the nervous system. Within RESIST our focus is on neurovirological infections and in particular with herpes viruses. The most common neuroinfectios condition is herpes zoster that is caused by varicella zoster virus (VZV). Since the clinical course of VZV infection varies tremendously between patients we want to identify determinants for a complicated clinical course with involvement of the central nervous system or with disabling post zoster neuralgia (PZN).

We want to achieve this on one hand be investigating genetic determinants these patients and on the other hand by searching for biomarker in the cerebrospinal fluid of patients suffering VZV infection. These informations will give clues for a better clinical management of patients with VZV infections and may also be the basis to identify new targets for the treatment of severe courses of VZV infections.

Prof. Höglinger about his scientific work

Prof. Dr. Günter Höglinger – Curriculum Vitae

Current Position

  • Since 2019 Full Professor and Director Dept. of Neurology, Hannover Medical School (MHH)

Undergraduate and Postgraduate Training

  • 1993 BSc-equivalent in Physics (Vordiplom), University of Regensburg

  • 1999 Licence in Medicine (Approbation), Regierung von Unterfranken

  • 2000 MD (Dr. med., summa cum laude), Universities of Munich, Bern, Marburg

  • 2000 – 2004 Postdoctoral Researcher, Institute of Health and Medical Research (INSERM), Unit 679, Hôpital Salpêtrière, Paris, France (supervisor Etienne Hirsch)

  • 2007 Habilitation in Neurology, Philipps-University of Marburg

  • 2007 Board-certified Neurologist (Facharzt für Neurologie), Landesärztekammer Hessen

  • 2012 Qualification for Intensive Care Medicine (Zusatzbezeichnung Intensivmedizin), Landesärztekammer Hessen

Academic and Research Posts

  • 1999 – 2001 Staff Physician, Neurology, University Marburg, Germany

  • 2001 – 2004 Postdoc, Institute of Health and Medical Research (INSERM), Unit 679, Hôpital Salpêtrière, Paris, France

  • 2004 – 2011 Head of Experimental Neurology, Marburg University

  • 2008 – 2009 Senior Consultant, Dept. of Neurology, Marburg University

  • 2009 – 2011 Executive Consultant, Dept. of Neurology, Marburg University

  • 2010 – 2011 Head of Stroke Unit, Dept. of Neurology, Marburg University

  • 2011 Deputy Director, Dept. of Neurology, Marburg University

  • 2011 – 2019 Full Professor for Translational Neurodegeneration (W3, tenured), DZNE Munich & Senior Consultant in Neurology, Dept. of Neurology, Technical University Munich

  • 2017 – 2019 Coordinator of Clinical Research and Head of Clinical Trial Unit, German Center for Neurodegenerative Diseases (DZNE) Munich

Other Scientific Roles

  • Since 2010 Member, Scientific Advisory Board, CurePSP Foundation, New York, NY, USA

  • Since 2015 Member, Advisory Board, Prof. Klaus Thiemann Foundation, Berlin, Germany

  • 2017 – 2023 President (Incoming, Acting, Past), German Parkinson’s & Movement Disorders Society (DPG)

  • Since 2020 Chair, Scientific Advisory Board, German Parkinson Foundation, Berlin, Germany

  • Since 2021 Member, Steering Committee, Center for Clinical Trials, MHH

  • Since 2021 Member, PhD commission “Systems Neuroscience”, Hannover

  • Since 2021 Member, Board of Directors, Center for Systems Neuroscience, Hannover

Awards and Prizes

  • 2009 First Price for „Innovative therapeutic strategies for neurodegenerative disorders“ Dr. Walter und Luise Freundlich-Foundation

  • 2011 – 2016 Heisenberg-Professorship (W3), German Research Council (DFG)

  • 2017 Dingebauer Award for Parkinson research, German Society for Neurology (DGN)

  • 2020 Standout Achievement Award, CurePSP, New York, NY, USA

Recommended Links

For further information about Prof. Höglinger’s scientific work please check the following links:

10 Selected Publications

Stamelou M, Giagkou N, Whitwell JL, Kovacs G, Hoglinger GU. Evolving concepts for Progressive Supranuclear Palsy and other 4R-tauopathies. Nature Reviews Neurology, in Druck.

Dam T, Boxer AL, Golbe LI, Höglinger GU, Morris HR, Litvan I, Lang AE, Corvol JC, Aiba I, Grundman M, Yang L, Tidemann-Miller B, Kupferman J, Harper C, Kamisoglu K, Wald MJ, GrahamDL, Gedney L, O’Gorman J, Budd Haeberlein S; on behalf of the PASSPORT Study Group. Safety and efficacy of the monoclonal anti-tau antibody gosuranemab in progressive supranuclear palsy: the PASSPORT trial. Nature Medicine, 2021;27:1451-1457

Truong DJ, Phlairaharn T, Esswein B, Gruber C, Tumen D, Baligacs E, Armbrust N, Vaccaro FL, Lederer EM, Beck EM, Geilenkeuser J, Goppert S, Krumwiede L, Gratz C, Raffl G, Schwarz D, Zirngibl M, Zivanic M, Beyer M, Korner JD, Santl T, Evsyukov V, Strauss T, Schwarz SC, Hoglinger GU, Heutink P, Doll S, Conrad M, Giesert F, Wurst W, Westmeyer GG. Non-invasive and high-throughput interrogation of exon-specific isoform expression. Nat Cell Biol 2021;23(6):652-63.

Höglinger GU, Litvan I, Mendonca N, Wang D, Zheng H, Rendenbach-Mueller B, Lon HK, Jin Z, Fisseha N, Budur K, Gold M, Ryman D, Florian H; Arise Investigators. Safety and efficacy of tilavonemab in progressive supranuclear palsy: a phase 2, randomised, placebo-controlled trial. Lancet Neurology 2021;20(3):182-192

Jabbari E, Koga S, Valentino RR, Reynolds RH, Ferrari R, Tan MMX, Rowe JB, Dalgard CL, Scholz SW, Dickson DW, Warner TT, Revesz T, Höglinger GU, Ross OA, Ryten M, Hardy J, Shoai M, Morris HR; PSP Genetics Group. Genetic determinants of survival in progressive supranuclear palsy: a genome-wide association study. Lancet Neurology 2021;20(2):107-116

Kovacs GG, Lukic MJ, Irwin DJ, Arzberger T, Respondek G, Lee EB, Coughlin D, Giese A, Grossman M, Kurz C, McMillan CT, Gelpi E, Compta Y, van Swieten JC, Laat LD, Troakes C, Al-Sarraj S, Robinson JL, Roeber S, Xie SX, Lee VM, Trojanowski JQ, Höglinger GU. Distribution patterns and sequential stages of tau pathology in progressive supranuclear palsy. Acta Neuropathologica 2020;140(2):99-119.

Hopfner F*, Höglinger GU*, Kuhlenbaumer G, Pottegard A, Wod M, Christensen K, Tanner CM, Deuschl G. beta-adrenoreceptors and the risk of Parkinson’s disease. Lancet Neurology 2020;19(3):247-54. * gleicher Beitrag

Levin J, Maaß S, Schuberth M, Giese A, Oertel WH, Poewe W, Trenkwalder C, Wenning GK, Mansmann U, Südmeyer M, Eggert K, Mollenhauer B, Lipp A, Löhle M, Classen J, Münchau A, Kassubek J, Gandor F, Berg D, Egert-Schwender S, Eberhardt C, Paul F, Bötzel K, Ertl-Wagner B, Huppertz HJ, Ricard I, Höglinger GU; PROMESA Study Group. Safety and efficacy of epigallocatechin gallate in multiple system atrophy (PROMESA): a randomised, double-blind, placebo-controlled trial. Lancet Neurology 2019;18(8):724-735

Weber A, Schwarz SC, Tost J, Trümbach D, Winter P, Busato F, Tacik P, Windhorst AC, Fagny M, Arzberger T, McLean C, van Swieten JC, Schwarz J, Vogt Weisenhorn D, Wurst W, Adhikary T, Dickson DW, Höglinger GU*, Müller U*. Epigenome-wide DNA methylation profiling in Progressive Supranuclear Palsy reveals major changes at DLX1. Nature Communications. 2018;9:2929 * gleicher Beitrag

Höglinger GU, Melhem NM, Dickson DW, Sleiman PMA, Wang LS, Klei L, Rademakers R, de Silva R, Litvan I, Riley DE, van Swieten JC, Heutink P, Wszolek ZK, Uitti RJ Vandrovcova J, Hurtig HI, Gross RG, Maetzler W, Goldwurm S, Tolosa E, Borroni B, Pastor P, PSP Genetics Study Group, Cantwell LB, Han MR, Dillman A, van der Brug MP, Gibbs JR, Cookson MR, Hernandez DG, Singleton AB, Farrer MJ, Yu CE, Golbe LI, Revesz T, Hardy J, Lees AJ, Devlin B, Hakonarson H, Müller U, Schellenberg JD. Identification of common variants influencing risk of the tauopathy Progressive Supranuclear Palsy. Nature Genetics, 2011;43:699-705.

Contact

  Prof. Dr. Günter Höglinger
   Klinik für Neurologie
Medizinische Hochschule Hannover
  Carl-Neuberg-Str. 1
30625 Hannover
  +49 511 532 – 2390
  Hoeglinger.Guenter
@mh-hannover.de